Value of early metabolic response for predicting axillary pathological complete response during neoadjuvant systemic therapy in triple negative and HER2-amplified breast cancers: impact of tumor subtypes.

Date publication

septembre 2025

Journal

Cancer imaging : the official publication of the International Cancer Imaging Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr COUTANT Charles , Dr LADOIRE Sylvain , Pr COCHET Alexandre

Tous les auteurs :
Guichard L, Nunes P, Jankowski C, Bertaut A, Michel E, Ladoire S, Coutant C, Cochet A, Alberini JL

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40993786

Résumé

In the era of therapeutic de-escalation, the opportunity to move from systematic axillary lymph node dissection (ALND) to sentinel lymph node biopsy in axillary node-positive breast cancer patients after neoadjuvant systemic therapy (NST) is currently considered. The purpose of this study was to identify FDG-PET parameters associated with axillary pathological complete response (pRAx) in the most proliferative tumor subtypes, eg Triple Negative (TN) and HER2-amplified.

Mots clés

Axillary lymph node, Breast cancer, FDG PET, Neoadjuvant therapy, Response monitoring, Tumor subtype

Référence

Cancer Imaging. 2025 09 24;25(1):110